Nanomedicine Ex Machina: Design Strategies based on Clinical Relevance

Matthias G. Wacker

Nanomedicine Ex Machina: Design Strategies based on Clinical Relevance

4 July 2022 5 pm (GMT+2)

Campus Riedberg N100 0.15, Goethe University


Over the past decade, nanomedicines have conquered the global healthcare market. They were successfully used in cancer therapy and to deliver COVID19 vaccines. With a growing knowledge of their clinical performances, computer-based strategies can be applied to streamline formulation development. While early screening often relies on biochemical in vitro characterization, the regulatory framework requires physicochemical testing to identify and compare suitable prototypes. The term “clinical relevance” was coined by the US-FDA and describes methodologies that can be used to predict the in vivo performance in humans. The talk outlines a strategy to achieve clinical relevance while designing the latest generation of drug delivery systems.

Matthias G. Wacker is an Associate Professor in the Department of Pharmacy of the National University of Singapore (NUS). Initially, he studied Pharmacy at Goethe University in Frankfurt (Germany) where he obtained his doctoral degree in pharmaceutical technology. As a principal investigator, he has joined Jennifer Dressman and Jörg Kreuter in the Institute of Pharmaceutical Technology, Goethe University. There he accomplished his habilitation exploring the rational design of nanocarriers and was awarded the Venia legendi in pharmaceutical technology. Before joining NUS, he headed the Department of Pharmaceutical Technology and Nanosciences of the Fraunhofer IME in Frankfurt. Currently, he serves the European Journal of Pharmaceutics and Biopharmaceutics, Journal of Pharmacy and Pharmacology, and Frontiers in Chemistry as an editorial board member. Further, he is a scientific advisor to the Journal of Pharmaceutical Sciences editors. He was honored with the Eudragit® Best Paper Award (2014) and the Phoenix Pharmaceutics Science Award (2017) in recognition of his research excellence. From 2020 to 2025, he is a member of the General Chapters – Dosage Forms Expert Committee and the Expert Panel on New Advancements in In-Vitro Product Performance Testing of the United States Pharmacopeia. His research focuses on the development and characterization of nanomedicines following a quality-by-design approach. He explores novel biopredictive release methods that can be used to forecast the in-vivo performances of complex oral and injectable dosage forms.

About the speaker